目的 探索构建我国乳腺癌治疗药品的综合评价指标体系，从多维度评估药品的综合价值支持临床合理用药。方法 通过文献综述、专家咨询收集证据，构建评估框架体系，建立具体评估指标，进行指标量化与赋权，并对最终构建的指标体系制定评分细则。结果 15名咨询专家积极系数为1.00，权威系数为0.90，重要性和可行性协调系数分别为0.305和0.336。最终构建的指标体系包括6个维度下的14个二级指标：安全性、经济性、适宜性、可及性各2个，有效性和创新性各3个。其中，有效性、安全性、经济性所占权重较高，分别赋分39分、19分、14分。结论 构建的药品综合评价指标体系符合乳腺癌药品价值评估的需求，临床可通过该体系对药品评分比较，从而为临床探索基于价值的药品评分提供经验参考。

Objective To establish a comprehensive evaluation index system for breast cancer treatment drugs in China, and to assess the comprehensive value of drugs from multiple dimensions to support clinical rational use. Methods Literature review and expert consultation were conducted to collect evidence that establishes a system of an evaluation framework and specific evaluation indices. Further modify the comprehensive assessment framework to determine the final assessment index system. Weigh each indicator by the appropriate algorithm and define the corresponding scoring rules. Results The positivity coefficient of 15 consulting experts is 1.00, the average authority is 0.90, and the opinion coordination coefficients of the importance and feasibility were 0.305 and 0.336. With this evaluation frame, there were six first-level indicators which include safety, efficacy, economy, innovation, appropriateness, and accessibility in this system, which consists with 14 second-level indicators. safety, economy, appropriateness, and accessibility each for 2, efficacy and innovation each for 3. Among them, effectiveness, safety and economy are given higher weights, with 39, 19 and 14 points respectively. Conclusion The comprehensive drug evaluation index system constructed in this study meets the needs of drug value assessment for breast cancer, which can provide experience reference for exploration of clinical value-based drug evaluation system.

R979.1